Item

Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477) with pom-dex in RRMM

Campbell, V.
; 
Searle, E.
; 
Pawlyn, C.
; 
Bygrave, C.
; 
Gooding, S.
; 
Cavet, J.
; 
Jenner, M.
; 
Radhakrishnan, V.
; 
Knapper, S.
; 
El-Sharkaw, D.
... show 7 more
Citations
Altmetric:
Abstract
Authors
Campbell, V.
Searle, E.
Pawlyn, C.
Bygrave, C.
Gooding, S.
Cavet, J.
Jenner, M.
Radhakrishnan, V.
Knapper, S.
El-Sharkaw, D.
O'Nions, J.
Knurowski, T.
Clegg, K.
West, W.
Haynes, D.
Frese, K.
Somervaille, T.
Affiliation
Western Gen Hosp, Edinburgh, Scotland Christie NHS Fdn Trust, Manchester, England Univ Manchester, Manchester, England Royal Marsden Hosp NHS Fdn Trust, London, England Univ Hosp Wales, Cardiff, Wales Univ Oxford, Oxford, England Univ Southampton NHS Fdn Trust, Southampton, England Cardiff Univ, Cardiff, Wales UCL, London, England CellCentric Ltd, Cambridge, England
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Campbell V, Searle E, Pawlyn C, Bygrave C, Gooding S, Cavet J, et al. Tolerability and Clinical Activity of Novel First-In-Class Oral Agent, inobrodib (CCS1477) With Pom-Dex in RRMM. British journal of haematology. 2025 APR;206. PubMed PMID: WOS:001517858300258. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/628202
Embedded videos